Xolair 150 MG/ML autoinjectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FJXF0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,747
Award facts
- Contract value 100% obligated
- $1,747.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $1,747.44 to DMS Pharmaceutical Group Inc. on November 25, 2025, for the supply of Xolair 150 mg/ml autoinjector. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, specializing in distributing pharmaceuticals and medical consumables to federal agencies, particularly the Department of Defense. This delivery order was issued without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The contract utilizes firm fixed-price pricing with an ultimate completion date of December 17, 2025, and will be performed at the vendor's Park Ridge, Illinois facility.
This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036. The PPV-G GEN V program is part of a larger $30.3 billion federal acquisition strategy designed to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide. The parent contract structure includes a 30-month base period with three 30-month option periods, positioning DMS Pharmaceutical Group as a critical pharmaceutical supplier within the federal military medical system capable of fulfilling diverse specialized pharmaceutical requirements across multiple therapeutic categories.
Quick answers
Who was awarded contract SPE2DR26FJXF0?
SPE2DR26FJXF0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 25, 2025.
How much is contract SPE2DR26FJXF0 worth?
The government has obligated $1,747 on SPE2DR26FJXF0.
Is contract SPE2DR26FJXF0 an order under another contract?
Yes. SPE2DR26FJXF0 is a delivery order under SPE2DR25D9307, an indefinite delivery contract.
Was contract SPE2DR26FJXF0 competed?
The extent of competition for SPE2DR26FJXF0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award